JG
SAGE

Jefferies Group’s Sage Therapeutics SAGE Stock Holding History

Jefferies Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$362K Hold
9,250
– – ﹤0.01% 1157
2022
Q2 		$299K Buy
9,250
+4,750
+106% +$159K ﹤0.01% 1170
2022
Q1 		$149K Buy
4,500
+1,994
+80% +$75K ﹤0.01% 1311
2021
Q4 		$107K Sell
2,506
-1,494
-37% -$62.6K ﹤0.01% 1467
2021
Q3 		$177K Sell
4,000
-20,878
-84% -$957K ﹤0.01% 1483
2021
Q2 		$1.41M Buy
24,878
+5,878
+31% +$416K 0.01% 865
2021
Q1 		$1.42M Buy
19,000
+1,000
+6% +$82K 0.01% 783
2020
Q4 		$1.56M Sell
18,000
-9,500
-35% -$700K 0.01% 800
2020
Q3 		$1.68M Sell
27,500
-7,500
-21% -$380K 0.02% 634
2020
Q2 		$1.46K Buy
35,000
+24,635
+238% +$894K 0.02% 667
2020
Q1 		$298K Sell
10,365
-6,253
-38% -$362K ﹤0.01% 1527
2019
Q4 		$1.2M Buy
16,618
+3,394
+26% +$418K 0.01% 1356
2019
Q3 		$1.85M Buy
13,224
+3,295
+33% +$551K 0.01% 1136
2019
Q2 		$1.82M Sell
9,929
-6,571
-40% -$1.12M 0.01% 970
2019
Q1 		$2.62M Buy
16,500
+9,047
+121% +$1.31M 0.02% 765
2018
Q4 		$714K Buy
+7,453
New +$853K 0.01% 1327
2017
Q3 		– Sell
-14,000
Closed -$1.11M – 2578
2017
Q2 		$1.11M Buy
+14,000
New +$1.01M 0.01% 1239
2016
Q4 		– Sell
-26,326
Closed -$1.21M – 2440
2016
Q3 		$1.21M Sell
26,326
-16,784
-39% -$683K 0.01% 1187
2016
Q2 		$1.3M Buy
+43,110
New +$1.44M 0.01% 1057

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jefferies Group's SAGE Position: Q3 2022 in Review

Jefferies Group held its Sage Therapeutics (SAGE) position steady in Q3 2022 at 9,250 shares worth $362K. The position accounts for ﹤0.01% of the portfolio, ranked #1157.

Jefferies Group first reported a position in SAGE in Q2 2016 and has held it in 19 quarters since. The position peaked at $2.62M in Q1 2019. 200 funds tracked by Wall St. Rank hold SAGE as of Q3 2022.

  • Jefferies Group held 9,250 shares of Sage Therapeutics worth $362K as of Q3 2022.
  • Jefferies Group left its Sage Therapeutics share count unchanged in Q3 2022.
  • Sage Therapeutics made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1157 holding.
  • Jefferies Group first reported a position in Sage Therapeutics in Q2 2016 and has held it in 19 quarters since.
  • Jefferies Group's Sage Therapeutics position peaked at $2.62M in Q1 2019.
  • 200 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.